overweight

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

admin November 3, 2024 0

World Health Organization. Obesity and overweight. (2024).Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to...

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Bone and Joint Health Supplements Market Size to Hit USD 9.40 Bn by 2035

Mass cancellations of orthopedic surgeries likely within weeks over compensation dispute, doctors say

N.W.T. leaders say Ottawa is underfunding Indigenous health-care program by millions

Istios Health Expands Into Nephrology With Three Practice Partnerships

Could dentists help Europe beat cervical cancer?

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

You may have missed

Bone and Joint Health Supplements Market Size to Hit USD 9.40 Bn by 2035

Mass cancellations of orthopedic surgeries likely within weeks over compensation dispute, doctors say

N.W.T. leaders say Ottawa is underfunding Indigenous health-care program by millions

Istios Health Expands Into Nephrology With Three Practice Partnerships

Could dentists help Europe beat cervical cancer?